Clinical study - Sein métastatique RH+

SAFIR-TOR
Sein métastatique RH+
Essai clinique fermé
Public cible
Adulte
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women.
Description de l'essai
This is a prospective biomarker study to show that p4EBP1 staining predicts clinical benefit from treatment with everolimus in patients who are eligible for everolimus+exemestane treatment. This trial is not aimed at evaluating a drug activity. Everolimus and exemestane are prescribed within their approved indication as per usual practice and are not part of this trial.
Vignette
PAUL-HENRI COTTU
Investigateur principal